[go: up one dir, main page]

WO2025056020A1 - Protéine contenant un domaine robo et son utilisation médicale - Google Patents

Protéine contenant un domaine robo et son utilisation médicale Download PDF

Info

Publication number
WO2025056020A1
WO2025056020A1 PCT/CN2024/118721 CN2024118721W WO2025056020A1 WO 2025056020 A1 WO2025056020 A1 WO 2025056020A1 CN 2024118721 W CN2024118721 W CN 2024118721W WO 2025056020 A1 WO2025056020 A1 WO 2025056020A1
Authority
WO
WIPO (PCT)
Prior art keywords
robo
robo2
linker
robo1
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2024/118721
Other languages
English (en)
Chinese (zh)
Inventor
曹保华
张晓谦
徐金敬
高文杰
李元元
王瑞雪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tuo Jie Biopharmaceutical Co Ltd
Original Assignee
Beijing Tuo Jie Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuo Jie Biopharmaceutical Co Ltd filed Critical Beijing Tuo Jie Biopharmaceutical Co Ltd
Publication of WO2025056020A1 publication Critical patent/WO2025056020A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Definitions

  • the present disclosure relates to the field of biomedicine, and in particular to a protein comprising a ROBO domain and a pharmaceutical composition thereof, a preparation method, a medical use, and a method for preventing or treating diseases related to the ROBO-SLIT2 signaling pathway (eg, kidney disease).
  • diseases related to the ROBO-SLIT2 signaling pathway eg, kidney disease.
  • ROBO2 Roundabout Receptor 2
  • ROBO2-SLIT2 signaling pathway inhibits the activity of non-muscle myosin IIA (NMIIA) through the downstream SLIT/ROBO Rho GTPase activating protein 1 (SRGAP1), thereby affecting the formation of podocyte adhesion spots on the basement membrane, making podocytes more likely to fall off.
  • NMIIA non-muscle myosin IIA
  • SRGAP1 downstream SLIT/ROBO Rho GTPase activating protein 1
  • ROBO2 deficiency can alleviate the glomerular sclerosis and proteinuria phenotype of NMIIA heavy chain-deficient mice (Xueping Fan et al. JCI Insight. 2016; 1(19): e86934).
  • the present disclosure provides a class of recombinant ROBO proteins that have been modified by mutation, etc., which, as SLIT ligand traps, have stronger SLIT2 ligand neutralizing activity and stability, stronger SLIT2 neutralizing activity can reduce the volume and frequency of administration, and good stability, so that it can be developed into a more convenient formulation form to improve the compliance and ease of use of patients with chronic kidney disease.
  • the recombinant ROBO protein disclosed in the present disclosure can be used to prevent or treat diseases related to the ROBO-SLIT2 signaling pathway, such as podocyte-related nephropathy.
  • the present disclosure provides proteins comprising a ROBO domain and polynucleotides encoding the proteins, pharmaceutical compositions, and methods for treating or preventing diseases (eg, kidney disease) and related pharmaceutical uses.
  • diseases eg, kidney disease
  • the present disclosure provides a protein comprising a ROBO domain, wherein the ROBO domain comprises a circular cross-receptor 2 immunoglobulin-like domain 1 (ROBO2 Ig1).
  • ROBO2 Ig1 circular cross-receptor 2 immunoglobulin-like domain 1
  • the ROBO2 Ig1 has an amino acid mutation at one or more positions 17, 30, 32, 66, and 68 compared to the wild-type ROBO2 Ig1 (SEQ ID NO: 20), and the position numbers are the natural sequence numbers relative to the amino acid sequence shown in SEQ ID NO: 1.
  • the ROBO2 Ig1 has an amino acid mutation selected from the following compared to the wild-type ROBO2 Ig1:
  • the ROBO2 Ig1 has an amino acid mutation selected from the following compared to the wild-type ROBO2 Ig1:
  • the ROBO2 Ig1 has an amino acid mutation selected from the following compared to the wild-type ROBO2 Ig1:
  • the ROBO2 Ig1 has an amino acid mutation selected from the following compared to the wild-type ROBO2 Ig1:
  • the ROBO2 Ig1 comprises any one of SEQ ID NOs: 20, 11-14 or An amino acid sequence having at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%; the same below) identity with the polypeptide.
  • ROBO2 Ig1 which has an amino acid mutation at one or more positions 62, 64, 70, 72, 73 compared to the wild-type ROBO2 Ig1, and the position number is the natural sequence number relative to the amino acid sequence shown in SEQ ID NO: 1.
  • the position number is the natural sequence number relative to the amino acid sequence shown in SEQ ID NO: 1.
  • ROBO2 Ig1 which has amino acid mutations at one or more positions 19, 26, 28, 30, 70 compared to wild-type ROBO2 Ig1, and the position numbers are natural sequence numbers relative to the amino acid sequence shown in SEQ ID NO: 1. For example, compared to wild-type ROBO2 Ig1, there are amino acid mutations at one or more positions V19, P26, T28, N30, F70.
  • the ROBO domain in the protein also comprises a circular cross-receptor immunoglobulin-like domain 2 (ROBO Ig2).
  • ROBO Ig2 circular cross-receptor immunoglobulin-like domain 2
  • ROBO Ig2 is circular cross-receptor 1 immunoglobulin-like domain 2 (ROBO1 Ig2) or circular cross-receptor 2 immunoglobulin-like domain 2 (ROBO2 Ig2).
  • the ROBO1 Ig2 comprises an amino acid sequence as shown in SEQ ID NO: 25 or a sequence that is at least 90% (e.g., 95%) identical thereto, and the ROBO2 Ig2 comprises SEQ ID NO: 24 or a sequence that is at least 90% (e.g., 95%) identical thereto.
  • the ROBO domain in the protein further comprises one or more of the following i)-vii):
  • ROBO immunoglobulin-like domain 1 a linker between the ROBO immunoglobulin-like domain 1 and the immunoglobulin-like domain 2 (ROBO Ig1-2 linker),
  • ROBO immunoglobulin-like domain 3 ROBO Ig3
  • ROBO immunoglobulin-like domain 4 ROBO Ig4
  • ROBO immunoglobulin-like domain 4 post-linker ROBO Ig4 post-linker
  • ROBO in i)-vii) is ROBO1 or ROBO2.
  • ROBO pre-Ig1 comprises an amino acid sequence as shown in SEQ ID NO: 19.
  • the ROBO Ig1-2 linker comprises an amino acid sequence as shown in SEQ ID NO: 22 or 23.
  • the ROBO Ig2-3 linker comprises an amino acid sequence as shown in SEQ ID NO: 26 or 27.
  • ROBO Ig3 comprises an amino acid sequence as shown in SEQ ID NO: 28 or 29 or an amino acid sequence that has at least 90% (e.g., 95%) identity thereto.
  • the ROBO Ig3-4 linker comprises an amino acid sequence as shown in SEQ ID NO: 30 or 31.
  • ROBO Ig4 comprises an amino acid sequence as shown in SEQ ID NO: 32 or 33 or an amino acid sequence that has at least 90% (e.g., 95%) identity thereto.
  • the ROBO Ig4 rear linker comprises an amino acid sequence as shown in SEQ ID NO: 34 or 35.
  • the ROBO domain in the protein comprises a structure represented by formula (II)-(IV):
  • - is a peptide bond
  • a2, b2, c2, d2, e2, f2, g2, and h2 in formula (II)-(IV) can be independently selected from 0 or 1.
  • a2, b2, c2, d2, e2, f2, g2, and h2 are all 0.
  • a2 is 1, b2, c2, d2, e2, f2, g2, and h2 are all 0.
  • b2 and c2 are 1, and a2, d2, e2, f2, g2, and h2 are all 0.
  • a2, b2, c2 are 1, and d2, e2, f2, g2, and h2 are all 0. In some specific embodiments, a2, b2, c2, d2, e2, f2, g2, and h2 are all 0. In some specific embodiments, a2, b2, c2, d2, e2, f2, g2, and h2 are all 0. In some specific embodiments, a2, b2, c2, d2 are 1, and e2, f2, g2, and h2 are all 0. In some specific embodiments, a2, b2, c2, d2, e2 are 1, and f2, g2, and h2 are all 0.
  • a2, b2, c2, d2, e2, f2 are 1, and g2 and h2 are 0.
  • a2, b2, c2, d2, e2, f2, g2 are 1, and h2 is 0.
  • b2, c2, d2 are 1, and a2, e2, f2, g2, and h2 are all 0.
  • b2, c2, d2, e2 are 1, and a2, f2, g2, and h2 are all 0.
  • b2, c2, d2, e2, f2 are 1, and a2, g2, and h2 are all 0.
  • b2, c2, d2, e2, f2 are 1, and a2, g2, and h2 are all 0.
  • b2, c2, d2, e2, f2 are 1, and a2, g2, and h2 are all 0.
  • b2, c2, d2, e2, f2, g2, and h2 are 1, and a2 is 0.
  • a2 and c2 are 1, and b2, d2, e2, f2, g2, and h2 are all 0.
  • c2 is 1, and a2, b2, d2, e2, f2, g2, and h2 are all 0.
  • a ROBO domain which comprises any of SEQ ID NOs: 20, 11-14 or an amino acid sequence that is at least 90% (e.g., 95%) identical thereto.
  • a protein which comprises any one of SEQ ID NOs: 20, 11-14 or has or an amino acid sequence at least 90% (eg, 95%) identical thereto.
  • the present disclosure provides a protein comprising a ROBO domain comprising an extracellular region of circular X receptor 2 (ROBO2) or a portion thereof and an extracellular region of circular X receptor 1 (ROBO1) or a portion thereof.
  • ROBO2 circular X receptor 2
  • ROBO1 extracellular region of circular X receptor 1
  • the ROBO domain comprises an immunoglobulin-like domain of ROBO2 and an immunoglobulin-like domain of ROBO1.
  • the ROBO domain comprises any one or any combination of the immunoglobulin-like domains Ig1, Ig2, Ig3, Ig4, and Ig5 of ROBO2, and any one or any combination of the immunoglobulin-like domains Ig1, Ig2, Ig3, Ig4, and Ig5 of ROBO1.
  • the ROBO domain comprises a structure as shown in formula (I):
  • - is a peptide bond
  • a1, b1, c1, d1, e1, f1, and g1 in formula (I) can be independently selected from 0 or 1.
  • a1, b1, c1, d1, e1, f1, and g1 are all 0.
  • b1 is 1, and a1, c1, d1, e1, f1, and g1 are all 0.
  • a1, b1, is 1, and c1, d1, e1, f1, and g1 are all 0.
  • a1, b1, c1 is 1, and d1, e1, f1, and g1 are all 0.
  • a1, b1, c1, d1 is 1, and e1, f1, and g1 are all 0.
  • a1, b1, c1, d1, e1 is 1, and f1, and g1 are all 0.
  • a1, b1, c1, d1, e1, f1 are 1, and g1 is 0.
  • b1 is 1, and a1, c1, d1, e1, f1, and g1 are all 0.
  • b1 and c1 are 1, and a1, d1, e1, f1, and g1 are all 0.
  • b1, c1, d1 are 1, and a1, e1, f1, and g1 are all 0. In some specific embodiments, b1, c1, d1, e1 are 1, and a1, f1, and g1 are all 0. In some specific embodiments, b1, c1, d1, e1, f1 are 1, and a1, g1 are all 0. In some specific embodiments, b1, c1, d1, e1, f1, and g1 are 1, and a1 is 0. In some specific embodiments, a1 is 1, and b1, c1, d1, e1, f1, and g1 are all 0.
  • the ROBO domain comprises any one of the following 1)-15):
  • the ROBO domain may also include one or any combination of a ROBO1 pre-Ig1 sequence or a ROBO2 pre-Ig1 sequence, a ROBO1 Ig1-2 linker or a ROBO2 Ig1-2 linker, a ROBO1 Ig2-3 linker or a ROBO2 Ig2-3 linker, a ROBO1 Ig3-4 linker or a ROBO2 Ig3-4 linker, a ROBO1 Ig4 post-linker or a ROBO2 Ig4 post-linker.
  • the ROBO domain comprises any one of the following 16)-84):
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1;
  • ROBO2 pre-Ig1 sequence or ROBO1 pre-Ig1 sequence
  • ROBO2 Ig1 and ROBO1 Ig2
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO2 Ig2;
  • ROBO2 pre-Ig1 sequence or ROBO1 pre-Ig1 sequence
  • ROBO2 Ig1 and ROBO1 Ig2 and ROBO1 Ig3
  • ROBO2 pre-Ig1 sequence or ROBO1 pre-Ig1 sequence
  • ROBO2 Ig1 and ROBO1 Ig2 and ROBO2 Ig3
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO2 Ig2 and ROBO1 Ig3;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO2 Ig2 and ROBO2 Ig3;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig2 and ROBO1 Ig3 and ROBO1 Ig4;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig2 and ROBO2 Ig3 and ROBO1 Ig4;
  • ROBO2 pre-Ig1 sequence or ROBO1 pre-Ig1 sequence
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO2 Ig2 and ROBO2 Ig3 and ROBO1 Ig4;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig2 and ROBO1 Ig3 and ROBO2 Ig4;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig2 and ROBO2 Ig3 and ROBO2 Ig4;
  • ROBO2 pre-Ig1 sequence or ROBO1 pre-Ig1 sequence
  • ROBO2 pre-Ig1 sequence or ROBO1 pre-Ig1 sequence
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker);
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2 and ROBO1 Ig3
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2 and ROBO2 Ig3
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2 and ROBO1 Ig3 and ROBO1 Ig4
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2 and ROBO2 Ig3 and ROBO1 Ig4
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig1-2 linker ROBO2 Ig1-2 linker
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig1-2 linker and ROBO2 Ig2 and ROBO2 Ig3 and ROBO1 Ig4;
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2 and ROBO1 Ig3 and ROBO2 Ig4
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2 and ROBO2 Ig3 and ROBO2 Ig4
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig1-2 linker ROBO2 Ig2 and ROBO1 Ig3 and ROBO2 Ig4;
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig1-2 linker ROBO2 Ig1-2 linker
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker);
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2 and ROBO1 Ig3;
  • ROBO2 pre-Ig1 sequence or ROBO1 pre-Ig1 sequence
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO1 Ig3;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO2 Ig3;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2 and ROBO1 Ig3 and ROBO1 Ig4;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2 and ROBO2 Ig3 and ROBO1 Ig4;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO1 Ig3 and ROBO1 Ig4;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO2 Ig3 and ROBO1 Ig4;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2 and ROBO1 Ig3 and ROBO2 Ig4;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2 and ROBO2 Ig3 and ROBO2 Ig4;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO1 Ig3 and ROBO2 Ig4;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO2 Ig3 and ROBO2 Ig4;
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2 and ROBO1 Ig2-3 linker or ROBO2 Ig2-3 linker
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig2 and ROBO1 Ig2-3 linker or ROBO2 Ig2-3 linker
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2 and ROBO1 Ig2-3 linker or ROBO2 Ig2-3 linker
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2 and ROBO1 Ig2-3 linker or ROBO2 Ig2-3 linker
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig2 and ROBO1 Ig2-3 linker or ROBO2 Ig2-3 linker
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig2 and ROBO1 Ig2-3 linker or ROBO2 Ig2-3 linker
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker);
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker);
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker) and ROBO1 Ig3;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker) and ROBO2 Ig3;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker) and ROBO1 Ig3;
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker) and ROBO2 Ig3;
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2 and ROBO1 Ig2-3 linker or ROBO2 Ig2-3 linker
  • ROBO1 Ig3 or ROBO2 Ig3
  • ROBO1 Ig3-4 linker or ROBO2 Ig3-4 linker
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig2 and ROBO1 Ig2-3 linker or ROBO2 Ig2-3 linker
  • ROBO1 Ig3 or ROBO2 Ig3
  • ROBO1 Ig3-4 linker or ROBO2 Ig3-4 linker
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker) and ROBO2 Ig3 and ROBO1 Ig3-4 linker (or ROBO2 Ig3-4 linker);
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker) and ROBO1 Ig3 (or ROBO2 Ig3) and ROBO1 Ig3-4 linker (or ROBO2 Ig3-4 linker);
  • ROBO2 Ig1 and ROBO1 Ig1-2 connexon or ROBO2 Ig1-2 connexon
  • ROBO1 Ig2 and ROBO1 Ig2-3 connexon or ROBO2 Ig2-3 connexon
  • ROBO1 Ig3 or ROBO2 Ig3
  • ROBO1 Ig3-4 connexon or ROBO2 Ig3-4 connexon
  • ROBO1 Ig4 or ROBO2 Ig4
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig2 and ROBO1 Ig2-3 linker or ROBO2 Ig2-3 linker
  • ROBO1 Ig3 or ROBO2 Ig3
  • ROBO1 Ig3-4 linker or ROBO2 Ig3-4 linker
  • ROBO1 Ig4 or ROBO2 Ig4
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker) and ROBO2 Ig3 and ROBO1 Ig3-4 linker (or ROBO2 Ig3-4 linker) and ROBO1 Ig4 (or ROBO2 Ig4);
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker) and ROBO1 Ig3 (or ROBO2 Ig3) and ROBO1 Ig3-4 linker (or ROBO2 Ig3-4 linker) and ROBO1 Ig4 (or ROBO2 Ig4);
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO1 Ig2 and ROBO1 Ig2-3 linker or ROBO2 Ig2-3 linker
  • ROBO1 Ig3 or ROBO2 Ig3
  • ROBO1 Ig3-4 linker or ROBO2 Ig3-4 linker
  • ROBO1 Ig4 or ROBO2 Ig4 post-linker
  • ROBO2 Ig4 post-linker or ROBO2 Ig4 post-linker
  • ROBO2 Ig1 and ROBO1 Ig1-2 linker or ROBO2 Ig1-2 linker
  • ROBO2 Ig2 and ROBO1 Ig2-3 linker or ROBO2 Ig2-3 linker
  • ROBO1 Ig3 or ROBO2 Ig3
  • ROBO1 Ig3-4 linker or ROBO2 Ig3-4 linker
  • ROBO1 Ig4 or ROBO2 Ig4 post-linker
  • ROBO2 Ig4 post-linker or ROBO2 Ig4 post-linker
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO1 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker) and ROBO2 Ig3 and ROBO1 Ig3-4 linker (or ROBO2 Ig3-4 linker) and ROBO1 Ig4 (or ROBO2 Ig4) and ROBO1 Ig4 post-linker (or ROBO2 Ig4 post-linker);
  • ROBO2 pre-Ig1 sequence (or ROBO1 pre-Ig1 sequence) and ROBO2 Ig1 and ROBO1 Ig1-2 linker (or ROBO2 Ig1-2 linker) and ROBO2 Ig2 and ROBO1 Ig2-3 linker (or ROBO2 Ig2-3 linker) and ROBO1 Ig3 (or ROBO2 Ig3) and ROBO1 Ig3-4 linker (or ROBO2 Ig3-4 linker) and ROBO1 Ig4 (or ROBO2 Ig4) and ROBO1 Ig4 post-linker (or ROBO2 Ig4 post-linker).
  • the ROBO domain comprises structures selected from 1)-84) from N-terminus to C-terminus, for example, "2) ROBO2 Ig1 and ROBO1 Ig2" means that the protein comprises ROBO2 Ig1 and ROBO1 Ig2 from N-terminus to C-terminus.
  • the ROBO2 Ig1 is wild-type ROBO2 Ig1 (e.g., shown in SEQ ID NO: 20) or an amino acid sequence that has at least 90% (e.g., at least 95%) identity thereto.
  • the ROBO2 Ig1 is any of the amino acids provided herein.
  • a mutated ROB02 Ig1 eg, any one of SEQ ID NOs: 11-14, or an amino acid sequence having at least 90% (eg, at least 95%) identity thereto, or any one of A)-R) above).
  • the ROBO2 Ig 2 is the amino acid sequence shown in SEQ ID NO: 24 or has at least 90% (e.g., at least 95%) identity thereto.
  • the ROBO1 Ig 2 is the amino acid sequence shown in SEQ ID NO: 25 or has at least 90% (e.g., at least 95%) identity thereto.
  • the ROBO2 Ig 3 is the amino acid sequence shown in SEQ ID NO: 28 or has at least 90% (e.g., at least 95%) identity thereto.
  • the ROBO1 Ig 3 is the amino acid sequence shown in SEQ ID NO: 29 or has at least 90% (e.g., at least 95%) identity thereto.
  • the ROBO2 Ig 4 is the amino acid sequence shown in SEQ ID NO: 32 or has at least 90% (e.g., at least 95%) identity thereto.
  • the ROBO1 Ig 4 is the amino acid sequence shown in SEQ ID NO: 33 or has at least 90% (e.g., at least 95%) identity thereto.
  • the ROBO2 pre-Ig1 sequence is the amino acid sequence shown in SEQ ID NO: 19.
  • the ROBO1 pre-Ig1 sequence is the amino acid sequence shown in SEQ ID NO: 19.
  • the ROBO2 Ig1-2 linker is the amino acid sequence shown in SEQ ID NO: 22.
  • the ROBO1 Ig1-2 linker is the amino acid sequence shown in SEQ ID NO: 23.
  • the ROBO2 Ig 2-3 linker is the amino acid sequence shown in SEQ ID NO: 26.
  • the ROBO1 Ig 2-3 linker is the amino acid sequence shown in SEQ ID NO: 27.
  • the ROBO2 Ig 3-4 linker is the amino acid sequence shown in SEQ ID NO: 30.
  • the ROBO1 Ig 3-4 linker is the amino acid sequence shown in SEQ ID NO: 31.
  • the ROBO2 Ig4 rear linker is the amino acid sequence shown in SEQ ID NO: 34.
  • the ROBO1 Ig4 post-linker is the amino acid sequence shown in SEQ ID NO: 35.
  • a variant of ROB0 pre-Ig1 (ROB01 pre-Ig1 or ROB02 pre-Ig1) is provided, which has one or more (e.g., 2, 3, 4, 5, 6) compared to SEQ ID NO: 19. Amino acid substitutions, deletions and/or additions, while still maintaining the function of ROBO pre-Ig1.
  • a variant of ROBO pre-Ig1 is provided, which has one or more (e.g., 2, 3, 4, 5, 6) conservative amino acid substitutions compared to SEQ ID NO: 19, and the variant still maintains the function of ROBO pre-Ig1.
  • variants of ROBO2 Ig1-2 linker, ROBO1 Ig1-2 linker, ROBO2 Ig2-3 linker, ROBO1 Ig2-3 linker, ROBO2 Ig3-4 linker, ROBO1 Ig3-4 linker, ROBO2 Ig4 post-linker, and ROBO1 Ig4 post-linker are provided, which have one or more (e.g., 2, 3, 4) amino acid substitutions, deletions, and/or additions (e.g., conservative amino acid substitutions) compared with the aforementioned amino acid sequences provided by the present invention, and can still achieve the function of the linker.
  • the present disclosure provides a protein comprising (i) any one of the aforementioned ROBO domains of the present disclosure and (ii) a half-life (eg, in vivo half-life) extension domain.
  • the (ii) half-life (eg, in vivo half-life) prolonging domain may be located at the N-terminus or C-terminus of the (i) ROBO domain.
  • the (ii) half-life (e.g., in vivo half-life) extending domain includes but is not limited to human serum albumin (HSA), an HSA binding domain (e.g., an anti-HSA antibody, and also an anti-HSA single domain antibody), and an immunoglobulin domain.
  • HSA human serum albumin
  • HSA binding domain e.g., an anti-HSA antibody, and also an anti-HSA single domain antibody
  • an immunoglobulin domain e.g., immunoglobulin domain.
  • the immunoglobulin domain is an immunoglobulin Fc region.
  • the immunoglobulin Fc region is derived from the Fc region of human IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM.
  • the Fc region may include mutations, exemplary mutations include: any or any combination of L234A, L235A, G237A on IgG1; for example, L234A/L235A, L234A/L235A/G237A; any or any combination of F234A, L235A, S228P on IgG4, for example, F234A/L235A, S228P/F234A/L235A.
  • the Fc region includes C220S.
  • the IgG Fc region contains SEQ ID NO: 37-39 or an amino acid sequence that is at least 80% or at least 90% identical thereto.
  • the ROBO domain and (ii) the half-life (e.g., in vivo half-life) extension domain may be directly connected or connected via a linker.
  • the linker may be a non-functional amino acid sequence of 1-20 or more amino acids in length and without secondary structures.
  • the linker is a flexible linker; for example, G 4 S (SEQ ID NO: 54), GS, GAP, (G 4 S) 2 (SEQ ID NO: 55), (G 4 S) 3 (SEQ ID NO: 56), (G 4 S) 4 (SEQ ID NO: 57), (G 4 S) 5 (SEQ ID NO: 58), ASGS (SEQ ID NO: 59), etc.; for example, the linker is a (G x S) y linker, wherein x is selected from an integer of 1-5 (e.g., 2), and y is selected from an integer of 1-6; for example, the linker is GGSGGS (SEQ ID NO: 36), (G 4 S) 2 ; in some embodiments, the linker is absent, that is, y is 0.
  • a protein which comprises an amino acid sequence shown in any of SEQ ID NOs: 15-18, 40-53 or having at least 80%, at least 90% (e.g., at least 95%) identity thereto.
  • the protein containing the ROBO domain provided by the present disclosure has at least one property selected from the following:
  • (a) binds to human SLIT2 with a K D value of ⁇ 1 ⁇ 10 -7 M, such as ⁇ 1 ⁇ 10 -8 M, ⁇ 1 ⁇ 10 -9 M, ⁇ 1 ⁇ 10 -10 M, ⁇ 1 ⁇ 10 -11 M, ⁇ 1 ⁇ 10 -12 M , preferably ⁇ 1 ⁇ 10 -11 M.
  • the detection method is conventional in the art, such as that provided in Example 4 of the present disclosure.
  • the protein comprising the ROBO domain comprises an immunoglobulin Fc region (e.g., an IgG1 Fc region comprising 234A/L235A/237A), it has a prolonged in vivo (or plasma) half-life.
  • the in vivo half-life is increased by at least 1.5 times, preferably at least 2 times, such as at least 5 times, such as at least 10 times or more than 20 times compared to when the immunoglobulin Fc region is not included; for example, the increased in vivo half-life can be greater than 1, 2, 6, 12 hours, or greater than 24, 48 or 72 hours compared to when the immunoglobulin Fc region is not included.
  • a subject capable of inhibiting or reducing proteinuria in a subject, the subject being, for example, a rat, more for example, a rat passive Heimann nephritis model.
  • the construction method, administration regimen, and proteinuria detection method of the rat passive Heimann nephritis model are conventional in the art, such as those provided in Example 7 of the present disclosure.
  • the present disclosure provides variants of a protein comprising a ROBO domain, wherein the variant has one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) amino acid mutations compared to any one of SEQ ID NOs: 7-18; the amino acid mutations may be conservative amino acid substitutions and/or deletions or additions that do not affect the function.
  • the amino acid mutations may be conservative amino acid substitutions and/or deletions or additions that do not affect the function.
  • proteins disclosed herein encompass pharmaceutically acceptable salts thereof.
  • the present disclosure provides polynucleotides encoding the ROBO domain-containing proteins of the present disclosure.
  • the polynucleotide may be RNA, DNA or cDNA. According to some embodiments of the present disclosure, the polynucleotide of the present disclosure is an isolated polynucleotide.
  • the polynucleotides of the present disclosure may also be in the form of a vector, may be present in a vector and/or may be part of a vector, such as a plasmid, a cosmid, a YAC or a viral vector.
  • the vector may be, in particular, an expression vector, i.e., a vector that can provide for expression of a protein comprising a ROBO domain in vitro and/or in vivo (i.e., in a suitable host cell, host organism and/or expression system).
  • the expression vector typically comprises at least one polynucleotide of the present disclosure, which is operably linked to one or more suitable expression control elements (e.g., promoters, enhancers, terminators, etc.).
  • Regulatory elements and other elements useful or necessary for the expression of the protein comprising the ROBO domain of the present disclosure are, for example, promoters, enhancers, terminators, integration factors, selection markers, leader sequences, reporter genes.
  • polypeptides of the present invention can be prepared by known methods based on the amino acid sequence information of the polypeptides of the present invention.
  • the polypeptides may be prepared or obtained (eg by automated DNA synthesis and/or recombinant DNA techniques) and/or may be isolated from suitable natural sources.
  • a host cell that expresses or is capable of expressing one or more ROBO domain-containing proteins of the present disclosure, and/or a recombinant host cell containing a polynucleotide or vector of the present disclosure.
  • the host cell is a bacterial cell, a fungal cell, or a mammalian cell.
  • Bacterial cells include, for example, cells of Gram-negative bacterial strains (e.g., Escherichia coli strains, Proteus strains, and Pseudomonas strains) and Gram-positive bacterial strains (e.g., Bacillus strains, Streptomyces strains, Staphylococcus strains, and Lactococcus strains).
  • Gram-negative bacterial strains e.g., Escherichia coli strains, Proteus strains, and Pseudomonas strains
  • Gram-positive bacterial strains e.g., Bacillus strains, Streptomyces strains, Staphylococcus strains, and Lactococcus strains.
  • Fungal cells include, for example, cells of species of Trichoderma, Neurospora and Aspergillus; or cells of species of Saccharomyces (e.g., Saccharomyces cerevisiae), Schizosaccharomyces (e.g., Schizosaccharomyces pombe), Pichia (e.g., Pichia pastoris and Pichia methanolica) and Hansenula.
  • Saccharomyces e.g., Saccharomyces cerevisiae
  • Schizosaccharomyces e.g., Schizosaccharomyces pombe
  • Pichia e.g., Pichia pastoris and Pichia methanolica
  • Hansenula Hansenula
  • mammalian cells are such as HEK293 cells, CHO cells, BHK cells, HeLa cells, COS cells, and the like.
  • the present disclosure may also use amphibian cells, insect cells, plant cells, and any other cells known in the art for expressing heterologous proteins.
  • the cells of the present disclosure are not capable of developing into complete plants or animals.
  • the present disclosure provides a method for preparing a protein comprising a ROBO domain of the present disclosure, comprising:
  • ROBO domain-containing proteins of the present disclosure can be produced intracellularly in the cells as described above (e.g., in the cytoplasm, in the periplasm, or in inclusion bodies), then isolated from the host cells and optionally further purified; or they can be produced extracellularly (e.g., in the culture medium in which the host cells are cultured), then isolated from the culture medium and optionally further purified.
  • Recombinant immunoglobulin expression vectors can stably transfect cells.
  • Mammalian expression systems lead to glycosylation of antibodies, especially at the highly conserved N-terminus of the Fc region.
  • Stable clones are obtained by expressing antibodies that specifically bind to human antigens. Positive clones are expanded and cultured in serum-free medium in bioreactors to produce antibodies.
  • the culture fluid that secretes antibodies can be purified and collected using conventional techniques.
  • Antibodies can be filtered and concentrated using conventional methods. Soluble mixtures and polymers can also be removed using conventional methods, such as molecular sieves and ion exchange. The resulting product must be immediately frozen, such as at -70°C, or freeze-dried.
  • ROBO domain-containing protein of the present disclosure can also be obtained by other methods of producing proteins known in the art, such as chemical synthesis, including solid phase or liquid phase synthesis.
  • the composition is a pharmaceutical composition, which contains a preventively or therapeutically effective amount of the protein containing the ROBO domain of the present disclosure as described above, and/or a polynucleotide encoding the protein containing the ROBO domain, and one or more pharmaceutically acceptable carriers or excipients.
  • the pharmaceutical composition may contain 0.01 to 99% by weight of a protein containing a ROBO domain in a unit dose. In other specific embodiments, the amount of a protein containing a ROBO domain in a unit dose of the pharmaceutical composition is 0.1-2000 mg. In some specific embodiments, it is 1-1000 mg.
  • the present disclosure provides a kit or a product, which comprises any of the aforementioned proteins comprising a ROBO domain of the present disclosure and/or a nucleic acid molecule encoding a protein comprising a ROBO domain of the present disclosure.
  • the present disclosure provides a composition for detecting SLIT2, the composition comprising the protein comprising the ROBO domain of the present disclosure.
  • the present disclosure also provides a method, system or device for detecting SLIT2 in vivo or in vitro, which comprises using the protein comprising the ROBO domain of the present disclosure.
  • the in vitro detection method, system or device may, for example, include: (1) contacting a sample with a protein containing a ROBO domain of the present disclosure; (2) detecting a complex formed between the protein containing a ROBO domain of the present disclosure and the sample; and/or (3) contacting a reference sample (e.g., a control sample) with a protein containing a ROBO domain; and (4) determining the extent of complex formation between the protein containing a ROBO domain and the sample by comparison with the reference sample.
  • a change e.g., a statistically significant change
  • in complex formation in the sample as compared to the control sample or subject indicates the presence of SLIT2 in the sample.
  • the in vivo detection method, system or device may include: (1) administering a ROBO domain-containing protein of the present disclosure to a subject; and (2) detecting the formation of a complex between the ROBO domain-containing protein of the present disclosure and the subject. Detection may include determining the location or time of complex formation.
  • Antibodies that bind to the ROBO domain-containing protein may be directly or indirectly labeled with a detectable substance to facilitate detection of bound or unbound antibodies. Suitable detectable substances include a variety of enzymes, prosthetic groups, fluorescent substances, luminescent substances and radioactive substances.
  • Complex formation between the ROBO domain-containing protein of the present disclosure and serum albumin can be detected by measuring or visualizing antibodies that bind or do not bind to the ROBO domain-containing protein.
  • ELISA enzyme-linked immunosorbent assay
  • RIA radioimmunoassay
  • tissue immunohistochemistry the presence of serum albumin in a sample is analyzed by a competitive immunoassay using a standard labeled with a detectable substance and an unlabeled ROBO domain-containing protein of the present disclosure.
  • the living sample can be tissue cells, blood, plasma, serum, pancreatic juice, urine, feces, tissue fluid or culture medium.
  • the ROBO domain-containing proteins of the present disclosure can be labeled with a fluorophore or chromophore for detection purposes.
  • the present disclosure provides a method for treating and/or preventing a disease, comprising administering a therapeutically and/or preventively effective amount of a protein comprising a ROBO domain of the present disclosure to a subject in need thereof.
  • the present disclosure also provides a protein comprising a ROBO domain for use in a method for treating and/or preventing a disease, the method comprising administering a therapeutically and/or preventively effective amount of the protein comprising a ROBO domain of the present disclosure to a subject in need thereof.
  • the present disclosure also provides use of a protein comprising a ROBO domain in preparing a medicament for treating and/or preventing a disease.
  • the disease is a disease caused by abnormal upregulation of the ROBO-SLIT2 signaling pathway.
  • the disease is a kidney disease, including a podocyte-related kidney disease.
  • the disease is the glomerular disease, focal segmental glomerulosclerosis (FSGS).
  • FSGS focal segmental glomerulosclerosis
  • FIG1 shows that ROB02-Fc2.2 and the chimeric ligand trap of the present disclosure inhibit the binding of the ligand SLIT2-D2 to the cell surface human ROB02 receptor in a dose-dependent manner.
  • FIG. 2 shows that ROBO2-Fc2.2 and the chimeric ligand trap of the present disclosure are able to neutralize the ligand SLIT2-N, restoring the migration of neuronal cells in a dose-dependent manner.
  • FIG3 shows the effect of ROBO2-Fc2.2 and the chimeric ligand trap of the present disclosure in suppressing proteinuria in a rat passive Heimann nephritis model using a prophylactic dosing regimen.
  • ROBO Roundabout Receptor
  • Slit-guided ligand SLIT protein ligands.
  • ROBO receptors in vertebrates have been characterized: ROBO1/Dutt1; ROBO2; ROBO3/Rig-1 and ROBO4/Magic Roundabout.
  • sequence of human ROBO2 can be found in Uniprot Q9HCK4, and the sequence of human ROBO1 can be found in Uniprot Q9Y6N7.
  • Both ROBO1 and ROBO2 have an extracellular domain (ECD) structure, and the ECD contains five immunoglobulin-like (Ig-like) domains (Ig1, Ig2, Ig3, Ig4 and Ig5), followed by three fibronectin type 3 (FN3) repeat sequences.
  • Ig-like domains Ig1, Ig2, Ig3, Ig4 and Ig5
  • ROBO Ig The fork receptor immunoglobulin-like domain is abbreviated as ROBO Ig
  • the circular cross receptor 1 immunoglobulin-like domain 2 is abbreviated as ROBO1 Ig
  • the circular cross receptor 2 immunoglobulin-like domain 1 is abbreviated as ROBO2 Ig
  • the ROBO pre-immunoglobulin-like 1 is abbreviated as ROBO pre-Ig1;
  • the linker between ROBO Ig2 and ROBO Ig3 can be abbreviated as ROBO Ig2-3 linker
  • the ROBO Ig1-2 linker includes ROBO1 Ig1-2 linker and ROBO2 Ig1-2 linker; illustratively, the ROBO2 Ig1-2 linker is shown in SEQ ID NO: 22, and the ROBO1 Ig1-2 linker is shown in SEQ ID NO: 23.
  • Recombinant protein refers to a polypeptide produced by recombinant DNA technology. Generally speaking, the DNA encoding the polypeptide is inserted into a suitable expression vector and then introduced into a host cell to produce the recombinant protein.
  • protein or “protein” refers to any composition comprising amino acids and recognized as a protein by those skilled in the art.
  • the terms “protein”, “protein”, “peptide” and “polypeptide” are used interchangeably herein.
  • the protein comprising a ROBO domain of the present disclosure is a recombinant protein.
  • the recombinant ROBO protein of the present disclosure binds to the SLIT ligand, thereby hindering the binding of SLIT to the cellular ROBO receptor, and is therefore called a SLIT neutralizing ligand trap.
  • the ROBO domain-containing proteins of the present disclosure will bind to SLIT2 with an equilibrium dissociation constant (KD) of preferably 10-7 to 10-10 moles/liter (M), more preferably 10-8 to 10-10 moles/liter, even more preferably 10-9 to 10-10 or less as measured in a Biacore or KinExA or Fortibio assay. Any KD value greater than 10-4 M is generally considered to indicate non-specific binding.
  • Specific binding of a receptor to a ligand can be determined in any suitable manner known, including, for example, surface plasmon resonance (SPR) assays, Scatchard assays, and/or competitive binding assays (e.g., radioimmunoassays (RIA), enzyme immunoassays (ELISA), and sandwich competitive assays as described in the present disclosure.
  • SPR surface plasmon resonance
  • RIA radioimmunoassays
  • ELISA enzyme immunoassays
  • sandwich competitive assays as described in the present disclosure.
  • the constant region amino acid position numbering in this disclosure is based on the Eu index.
  • a “linker” is a molecule or group of molecules that binds two separate entities (e.g., a ROBO domain and an immunoglobulin Fc region) to each other, and the linker can provide a spacer between the two entities to enable them to achieve a conformation in which they, for example, specifically bind to their cognate ligand (e.g., a SLIT ligand).
  • the linker is, for example, a polypeptide linker, and can be expressed as a component of a recombinant protein using standard recombinant DNA techniques well known in the art.
  • inhibitor or “block” are used interchangeably and encompass both partial and complete inhibition/blocking.
  • homology and “identity” refer to the sequence similarity between two polynucleotide sequences or between two polypeptides.
  • positions in the two compared sequences are occupied by the same base or amino acid monomer subunit, for example, if every position of the two DNA molecules is occupied by adenine, then the molecules are homologous at that position.
  • the percentage of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared ⁇ 100.
  • sequences are optimally aligned, if 6 out of 10 positions in the two sequences are matched or homologous, then the two sequences are 60% homologous; if 95 out of 100 positions in the two sequences are matched or homologous, then the two sequences are 95% homologous.
  • the comparison is made when the two sequences are aligned to obtain the maximum percentage of homology.
  • Constant amino acid substitution refers to the replacement of one or more amino acid residues in a protein or polypeptide with conservative amino acids, where the chemical structure of the amino acid residue before the replacement is similar to that of the amino acid residue after the replacement, and the replacement The function, activity or other biological properties of the protein or polypeptide are less affected or substantially unaffected.
  • the conservative amino acid substitution is well known in the art, for example, a conservative amino acid substitution is preferably a substitution of an amino acid in the following groups (i)-(v) by another amino acid residue in the same group:
  • Particularly preferred conservative amino acid substitutions are as follows: Ala is replaced by Gly or Ser; Arg is replaced by Lys; Asn is replaced by Gln or His; Asp is replaced by Glu; Cys is replaced by Ser; Gln is replaced by Asn; Glu is replaced by Asp; Gly is replaced by Ala or Pro; His is replaced by Asn or Gln; Ile is replaced by Leu or Val; Leu is replaced by Ile or Val; Lys is replaced by Arg, Gln or Glu; Met is replaced by Leu, Tyr or Ile; Phe is replaced by Met, Leu or Tyr; Ser is replaced by Thr; Thr is replaced by Ser; Trp is replaced by Tyr; Tyr is replaced by Trp or Phe; Val is replaced by Ile or Leu.
  • Nucleic acid “nucleic acid molecule,” or “polynucleotide” are used interchangeably in the present disclosure and refer to any DNA molecule or RNA molecule that is single-stranded or double-stranded and, in the case of single-stranded, its complementary sequence, preferably double-stranded DNA.
  • a nucleic acid is "operably linked” when it is placed in a functional relationship with another nucleic acid sequence.
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto.
  • the vector is a "plasmid", which refers to a circular double-stranded DNA loop into which other DNA segments can be connected.
  • the vector is a viral vector, in which other DNA segments can be connected to the viral genome.
  • the vector in the present disclosure can replicate autonomously in the host cell introduced into them (e.g., bacterial vectors and additional mammalian vectors with a bacterial origin of replication) or can be integrated into the genome of the host cell after introducing the host cell, thereby replicating with the host genome (e.g., non-additional mammalian vectors).
  • progeny As used herein, the expressions "cell,” “cell line,” and “cell culture” are used interchangeably, and all such designations include progeny. Thus, “transformants” and “transformed cells” include the primary subject cell and cultures derived therefrom, without regard to the number of passages. It should also be understood that all progeny may not be precisely identical in DNA content, due to deliberate or unintentional mutations. Mutant progeny having the same function or biological activity as screened for in the originally transformed cell are included. Where different designations are intended, this is clear from the context.
  • Host cell includes an individual cell or cell culture that can be or has been a recipient of a vector for incorporating a nucleic acid insert.
  • Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
  • Host cells include cells transfected and/or transformed in vivo with a nucleic acid of the present disclosure.
  • Cell Cell line
  • cell culture are used interchangeably, and all such designations include progeny. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or unintentional mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell are included.
  • “Pharmaceutical composition” refers to a mixture containing one or more fusion proteins, proteins containing ROBO domains, polynucleotides and other components described in the present disclosure, such as physiologically/pharmaceutically acceptable carriers, diluents, buffers or excipients.
  • physiologically/pharmaceutically acceptable carriers such as physiologically/pharmaceutically acceptable carriers, diluents, buffers or excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient and thus exert biological activity.
  • administering when applied to an animal, a human, a subject, a cell, a tissue, an organ, or a biological fluid, refers to the contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with an animal, a human, a subject, a cell, a tissue, an organ, or a biological fluid.
  • administering can refer to, for example, treatment, pharmacokinetics, diagnosis, research, and experimental procedures. Treatment of cells includes contact of an agent with a cell, and contact of an agent with a fluid, wherein the fluid is in contact with the cell.
  • administering also mean treating a cell in vitro and ex vivo by an agent, a diagnostic, a combination composition, or by another cell.
  • Treatment when applied to humans, veterinary medicine, or research subjects, refers to therapeutic treatment, prophylactic or preventative measures, research and diagnostic applications.
  • Treatment means administering an internal or external therapeutic agent (such as a fusion protein disclosed herein) to a subject who has one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect.
  • a therapeutic agent is administered in an amount effective to alleviate one or more symptoms of a disease in a treated patient or population to induce regression of such symptoms or inhibit the development of such symptoms to any clinically measurable degree.
  • the amount of a therapeutic agent effective to alleviate any specific disease symptom may vary according to a variety of factors, such as the patient's disease state, age, and weight, and the ability of the drug to produce the desired therapeutic effect in the patient.
  • Whether the disease symptom has been alleviated can be evaluated by any clinical detection method commonly used by doctors or other professional health care personnel to evaluate the severity or progression of the symptom.
  • the embodiments of the present disclosure e.g., treatment methods or products
  • may not be effective in alleviating every target disease symptom they should alleviate the target disease symptoms in a statistically significant number of patients as determined by any statistical test known in the art, such as Student's t-test, chi-square test, U test according to Mann and Whitney, Kruskal-Wallis test (H test), Jonckheere-Terpstra test, and Wilcoxon test.
  • the “subject” and “patient” of the present disclosure refer to mammals, especially primates, and especially humans.
  • At least 95% (sequence) identity encompasses at least 95%, at least 96%, at least 97%, At least 98%, at least 99%, or 100% (sequence) identity, and ranges between any two of the foregoing values, including integers and decimals;
  • at least 90% (sequence) identity encompasses at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% (sequence) identity, and ranges between any two of the foregoing values, including integers and decimals;
  • at least 80% (sequence) identity encompasses at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% (sequence) identity, and ranges between any two of the foregoing values
  • ROBO2 ligand trap refers to human ROBO2 unless otherwise specified.
  • the italic double underline is ROBO2 pre-Ig1; the underlined part is ROBO2 Ig1; the double underline is the linker between ROBO2Ig1 and ROBO2 Ig2, and the curved line is ROBO2 Ig2; the dotted line is the ROBO2 Ig2-Ig3 linker; the italic part is the GS linker; the rest is the antibody constant region, which removes the Fc-mediated effect of hIgG1-Fc with C220S/L234A/L235A/G237A.
  • the italic double underlined part is the ROBO2 pre-Ig1 sequence; the underlined part is ROBO2 Ig1; the italic part is the GS linker; the rest is the antibody constant region, which is the hIgG1-Fc with C220S/L234A/L235A/G237A that removes the Fc-mediated effect.
  • ROBO1 ligand trap refers to human ROBO1 unless otherwise specified.
  • the italic double underlined part is the ROBO1 pre-Ig1 sequence; the underlined part is ROBO1 Ig1; the italic part is the GS linker; the rest is the antibody constant region, which is hIgG1-Fc containing C220S/L234A/L235A/G237A.
  • SLIT2 refers to human SLIT2 unless otherwise specified.
  • the underlined part is the extracellular region of human SLIT2, the second LRR domain of human Slit2 (SLIT2 D2); the italic part is the GS linker; the curved part is the avi-tag; and the dotted part is the his-tag.
  • the above three saturation mutation libraries were constructed based on the wild-type ROBO2 Ig1 domain, and clones were randomly selected for sequencing to verify the quality of the library. Subsequently, the phage library and the corresponding SLIT2-D2 were screened.
  • the ROBO2 Ig1 domain with high affinity to human SLIT2-D2-avi-his (SEQ ID NO: 4) protein was obtained by screening the phage library. 20 ⁇ g of human SLIT2-D2-avi-his biotin protein was combined with 100 uL Dynabeads TM M-280 Streptavidin, and then placed at 37°C for one hour and blocked with 2% skim milk at room temperature for 1 hour. The ROBO2 Ig1 domain saturated mutant phage display library was added and allowed to act at room temperature for 1 hour. The phages that did not bind were removed by washing 9 times with PBST (0.05% Tween-20) solution.
  • the phages that specifically bound to human SLIT2-D2 were eluted with 1 mg/mL trypsin and infected with Escherichia coli TG1 in logarithmic phase growth to produce and purify phages for the next round of screening. The above steps were repeated 5 times for screening, and 96 monoclonal colonies were selected from the positive clones enriched by screening and packaged into phage single-chain antibodies for phage ELISA test. 2 ⁇ g/mL of SLIT2-D2 protein was coated on the ELISA plate, and the phage supernatant diluted with blocking solution was added, and detected with anti-M13 HRP (Sino Biological, Cat.#11973-MM05T-H).
  • the clones with OD450 value/background value>5 in the ELISA binding experiment were sequenced, the sequences were cloned into eukaryotic expression vectors, the purified proteins were expressed, and further screened by cell blocking experiments. A total of 4 mutants with improved affinity and function were screened (Table 2).
  • the italicized one is ROBO2-Ig1
  • the single underline is the amino acid mutation site
  • the double underline is the ROBO2 Ig1-2 linker
  • the dotted line is ROBO2 Ig2
  • the curved line is the ROBO2 Ig2-3 linker
  • the hyperbola is the GS linker
  • the rest is the antibody constant region, which is hIgG1-Fc of C220S/L234A/L235A/G237A
  • the italic double underline is the ROBO2 pre-Ig1 sequence.
  • ROBO2 Ig1 mutant sequences obtained by screening are as follows:
  • ROBO2 Ig2 had a site that was prone to breakage. Replacing it with the ROBO1 Ig2 sequence could avoid this breakage site.
  • ROBO2 Ig1/ROBO1 Ig2 chimeras were constructed, and the ROBO1Ig1-2 linker, ROBO1 Ig2-3 linker, GS linker, and hIgG1 Fc hinge region sequences were replaced or optimized to further screen for target proteins with better stability.
  • the italicized one is ROBO2-Ig1 (SEQ ID NO: 11-14), the double underlined straight line is ROBO1 Ig1-2 linker, the dotted line is ROBO1-Ig2, the double underlined curved line is ROBO1 Ig2-3 linker, and the rest are hIgG1-Fc with L234A/L235A/G237A and EPKSC removed in the hinge region; the italicized double underlined one is the ROBO2 pre-Ig1 sequence.
  • the affinity of the example chimeric ligand trap 0044-0520 and the positive control ROBO2-Fc2.2 to human or rat SLIT2 D2 was determined using a Biacore T200 (GE Healthcare) instrument.
  • the ligand trap protein to be detected was captured on the chip surface using the chip Series S sensor chip Protein A (GE Healthcare, Cat.#29127556), and then different concentrations of protein human/rat SLIT2 D2-his (SEQ ID NO: 5-6) were passed over the chip surface.
  • the reaction signal was detected in real time to obtain the binding Dissociation curve, the binding force constant is obtained by fitting.
  • the solution used in the experiment is HBS-EP solution (10mM HEPES, 150mM NaCl, 3mM EDTA, 0.005% P20, pH 7.4).
  • the chip was washed and regenerated with pH1.5 Glycine (GE Healthcare, Cat.#BR-1003-54) solution.
  • the affinity results are shown in Table 3.
  • the results show that the exemplary mutant 0044-0520 disclosed in the present invention has a better affinity for human SLIT2D2-his and rat SLIT2 D2-his than the positive control ROBO2-Fc2.2.
  • This example detects whether the chimeric ligand trap protein acts as a ligand trap by competitively binding to the ligand SLIT2 with the ROBO2 receptor expressed on the cell surface.
  • HEK293E cells were suspended and transfected with human ROBO2 receptor plasmid (SinoBiological, Cat.#HG10310-CF) by Lipofectamine TM 2000 (Invitrogen, Cat.#11668027). 60 hours after transfection, cells were collected by centrifugation, washed once with PBS buffer, counted the live cells and resuspended to a concentration of 500,000 cells/50uL PBS, incubated with 5nM human SLIT2-D2 (SEQ ID NO: 5), different concentrations of ligand trap protein, and 10ug/mL heparin sodium in PBS, incubated at 4°C for 1 hour, and washed twice with PBS to wash away unbound proteins.
  • GraphPad Prism 9 was used to plot the nonlinear fitting and three-parameter non-logarithmic inhibitor response model. Example results are shown in Figure 1. 0044-0520 inhibited the binding of the ligand SLIT2-D2 to the human ROBO2 receptor in a dose-dependent manner, and the blocking effect of 0044-0520 was significantly better than that of the positive control ROBO2-Fc2.2.
  • This example detects the neutralizing ability of chimeric ligand traps on SLIT2-N, and relieves the repulsive guiding effect of ROBO2-SLIT2 on the migration of subependymal neurons in the forebrain of rat pups.
  • the subependymal neurons of the rat forebrain migrate along the rostral migration channel to the olfactory bulb and develop into olfactory bulb interneurons.
  • SLIT2 has an repulsive guiding effect on the migration of the above-mentioned nerve cells, and is ROBO2-dependent.
  • Forebrain subependymal neuron tissue blocks were isolated from SD rat pups (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., gender not limited, 3-4 days old) and cut into 0.5mm*0.5mm*0.5mm size.
  • Matrigel and DMEM complete culture medium containing 10% serum were mixed in a volume ratio of 4:1 (Matrigel BD, Cat.#354234; DMEM culture medium thermo, Cat.#11995073; fetal bovine serum Gibco, Cat.#10099-141c), and about 50 ⁇ L of the above mixture was pipetted to the center of the glass bottom of a 35mm glass-bottomed confocal culture dish (Biyuntian, Cat.#FCFC020), and the tissue blocks were embedded therein and placed at 37°C for half an hour to allow the matrigel to solidify.
  • the ligand trap can restore the migration of neuronal cells in a dose-dependent manner, and the ligand trap protein concentration and neuronal migration distance were analyzed by GraphPad Prism9 software to perform three-parameter fitting to obtain EC 50 . See Table 5 for example measurement results.
  • GraphPad Prism 9 was used to plot the responses using a nonlinear, three-parameter non-log agonist-response model and a two-way ANOVA ( Test, * ⁇ 0.05), the example results are shown in Figure 2, the ligand trap restored the migration of neuronal cells in a dose-dependent manner, and the SLIT2-N neutralizing activity of the 0044-0520 ligand was significantly better than that of the positive control ROBO2-Fc2.2.
  • Example 7 In vivo efficacy verification of chimeric ligand trap in rat nephritis model
  • This example tests the effect of chimeric ligand traps in inhibiting proteinuria in a rat passive Heimann nephritis model.
  • Lewis rats (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., male, 8 weeks old) were adaptively raised for 1 week. Rats were randomly grouped and numbered according to their weight, and sheep anti-rat Fx1A (Probetex, Cat. #PTX-002S) serum was injected through the tail vein to induce the rats to produce an immune response to the injected serum, complement activation, causing podocyte foot process elimination and then proteinuria renal damage phenotype. A preventive dosing regimen was adopted, and the ligand trap protein was initially administered subcutaneously one day before the injection of anti-rat serum, with a dose of 25 mg/kg, once every two days, for a total of 6 times.
  • sheep anti-rat Fx1A Probetex, Cat. #PTX-002S
  • Rat urine samples were collected before and after serum modeling through metabolic cages, and urine albumin and urine creatinine (Invitrogen, Cat. #EIACUN) were detected respectively, and urine albumin/creatine was calculated.
  • the difference of UACR among treatment groups was analyzed by GraphPad Prism9.
  • Rats began to have proteinuria on the 2nd to 3rd day of modeling and reached a peak around the 11th day.
  • the proteinuria reduction rate in the positive control ROBO2-Fc2.2 treatment group was 30.4%
  • the proteinuria reduction rate in the 0044-0520 treatment group was increased to 45.8%.
  • the proteinuria levels of the two treatment groups were significantly different, one-way analysis of variance (Tukey test, * ⁇ 0.05).
  • sequences disclosed herein also include:
  • the italic double underline is ROBO2 pre-Ig1
  • the italic is ROBO2-Ig1 (SEQ ID NO: 13)
  • the double underlined straight line is ROBO1 Ig1-2 linker
  • the dotted line is ROBO1-Ig2
  • the double underlined curved line is ROBO1Ig2-3 linker
  • the single underline is ROBO1 Ig3 and ROBO1 Ig3-4 linker
  • the rest are hIgG1-Fc.
  • the italic double underline is ROBO2 pre-Ig1
  • the italic is ROBO2-Ig1 (SEQ ID NO: 13)
  • the double underlined straight line is ROBO1 Ig1-2 linker
  • the dotted line is ROBO1-Ig2
  • the double underlined curved line is ROBO1Ig2-3 linker
  • the single underline is ROBO1 Ig3-linker and ROBO1 Ig3-4 linker
  • the single curved line is ROBO1 Ig4 and ROBO1 Ig4 post-linker
  • the rest are hIgG1-Fc.
  • the italic double underline is ROBO2 pre-Ig1
  • the italic is ROBO2-Ig1 (SEQ ID NO: 13)
  • the double underlined straight line is ROBO1 Ig1-2 linker
  • the dotted line is ROBO1-Ig2
  • the double underlined curved line is ROBO1Ig2-3 linker
  • the single underline is ROBO1 Ig3-linker and ROBO1 Ig3-4 linker
  • the single curved line is ROBO2 Ig4 and ROBO2 Ig4 post-linker
  • the rest are hIgG1-Fc.
  • the italic double underline is ROBO2 pre-Ig1
  • the italic is ROBO2-Ig1 (SEQ ID NO: 13)
  • the double underlined straight line is ROBO1 Ig1-2 linker
  • the dotted line is ROBO1-Ig2
  • the double underlined curved line is ROBO1Ig2-3 linker
  • the single underline is ROBO2 Ig3 and ROBO2 Ig3-4 linker
  • the rest are hIgG1-Fc.
  • the italic double underline is ROBO2 pre-Ig1
  • the italic is ROBO2-Ig1 (SEQ ID NO: 13)
  • the double underlined straight line is ROBO1 Ig1-2 linker
  • the dotted line is ROBO1-Ig2
  • the double underlined curved line is ROBO1 Ig2-3 linker
  • the single underline is ROBO2 Ig3 and ROBO2 Ig3-4 linker
  • the single curved line is ROBO2 Ig4 and ROBO2 Ig4 post-linker, the rest are hIgG1-Fc.
  • the italic double underline is ROBO2 pre-Ig1
  • the italic is ROBO2-Ig1 (SEQ ID NO: 13)
  • the double underlined straight line is ROBO1 Ig1-2 linker
  • the dotted line is ROBO1-Ig2
  • the double underlined curved line is ROBO1 Ig2-3 linker
  • the single underline is ROBO2 Ig3 and ROBO2 Ig3-4 linker
  • the single curved line is ROBO1 Ig4 and ROBO1 Ig4 post-linker
  • the rest are hIgG1-Fc.
  • the italic double underline is the ROBO2 pre-Ig1 sequence
  • the italic is ROBO2-Ig1 (SEQ ID NOs: 11-14)
  • the double underlined straight line is the ROBO1 Ig1-2 linker
  • the dotted line is ROBO1-Ig2
  • the double underlined curved line is the ROBO1 Ig2-3 linker.
  • the italic is ROBO2-Ig1 (SEQ ID NOs: 11-14)
  • the double underlined straight line is the ROBO1 Ig1-2 linker
  • the dotted line is ROBO1-Ig2
  • the double underlined curved line is the ROBO1 Ig2-3 linker.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une protéine comprenant un domaine ROBO et son utilisation médicale, et concerne en particulier une protéine comprenant un domaine ROBO et son utilisation dans le traitement de maladies liées à une régulation à la hausse anormale d'une voie de signalisation ROBO-SLIT2.
PCT/CN2024/118721 2023-09-14 2024-09-13 Protéine contenant un domaine robo et son utilisation médicale Pending WO2025056020A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202311184604.1 2023-09-14
CN202311184604 2023-09-14

Publications (1)

Publication Number Publication Date
WO2025056020A1 true WO2025056020A1 (fr) 2025-03-20

Family

ID=95020939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2024/118721 Pending WO2025056020A1 (fr) 2023-09-14 2024-09-13 Protéine contenant un domaine robo et son utilisation médicale

Country Status (2)

Country Link
TW (1) TW202511284A (fr)
WO (1) WO2025056020A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102884076A (zh) * 2010-04-14 2013-01-16 赛诺菲 Robo 1-Fc融合蛋白及其用于治疗肿瘤的用途
CN103703021A (zh) * 2010-12-23 2014-04-02 赛诺菲 用于治疗肝癌的Robo1-Fc融合蛋白
CN108977453A (zh) * 2017-06-02 2018-12-11 阿思科力(苏州)生物科技有限公司 一种以robo1为靶点的嵌合抗原受体细胞及其制备和应用
CN109810995A (zh) * 2017-12-06 2019-05-28 阿思科力(苏州)生物科技有限公司 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用
CN110709415A (zh) * 2017-06-02 2020-01-17 辉瑞大药厂 重组robo2蛋白、组合物、方法及其用途
CN113462652A (zh) * 2021-09-06 2021-10-01 阿思科力(苏州)生物科技有限公司 细胞、免疫治疗产品、基因编辑方法、细胞制备方法及应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102884076A (zh) * 2010-04-14 2013-01-16 赛诺菲 Robo 1-Fc融合蛋白及其用于治疗肿瘤的用途
CN103703021A (zh) * 2010-12-23 2014-04-02 赛诺菲 用于治疗肝癌的Robo1-Fc融合蛋白
CN108977453A (zh) * 2017-06-02 2018-12-11 阿思科力(苏州)生物科技有限公司 一种以robo1为靶点的嵌合抗原受体细胞及其制备和应用
CN110709415A (zh) * 2017-06-02 2020-01-17 辉瑞大药厂 重组robo2蛋白、组合物、方法及其用途
CN109810995A (zh) * 2017-12-06 2019-05-28 阿思科力(苏州)生物科技有限公司 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用
CN113462652A (zh) * 2021-09-06 2021-10-01 阿思科力(苏州)生物科技有限公司 细胞、免疫治疗产品、基因编辑方法、细胞制备方法及应用

Also Published As

Publication number Publication date
TW202511284A (zh) 2025-03-16

Similar Documents

Publication Publication Date Title
JP6783797B2 (ja) 抗がん融合ポリペプチド
EP3816625B1 (fr) Compositions et procédés de modulation de facteur de croissance
JP7212009B2 (ja) Ｃｘｃｒ４結合分子
CN110770250B (zh) 用于兽医用途的il4/il13受体分子
CN102216323B (zh) 用于调节慢性炎症反应和治疗自身免疫性疾病的源自il-4的肽
CN120623353A (zh) 多特异性wnt替代分子和其用途
CN115772225B (zh) 靶向TNF-α和IL-23的双特异性纳米抗体及其用途
CN114380906B (zh) 一种抗il-17a的单域抗体及其用途
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
JP2022520862A (ja) 新規組換えジアミンオキシダーゼおよび過剰ヒスタミンによって特徴づけられる疾患の治療のためのその使用
AU2009253623B2 (en) A soluble tumor necrosis factor receptor mutant
CN110234760B (zh) 用于治疗年龄相关性黄斑变性的肽
CN116685605A (zh) 靶向il-17a和il-36r的双特异性抗体及其应用
WO2025056020A1 (fr) Protéine contenant un domaine robo et son utilisation médicale
JP2023552919A (ja) Ｗｎｔ受容体ｒｙｋに対する抗体バリアント
CN111100210B (zh) 一种Fc融合蛋白及其应用
CN111378039A (zh) 治疗恶性肿瘤的抗体及其应用
WO2024235270A1 (fr) Inhibiteur du complément, son procédé de préparation et son utilisation
US20230091105A1 (en) Chimeric fusions between c4-binding protein c-terminal segment and angiopoietin-1 fibrinogen-like domain as angiopoietin mimetics and tie2 agonists to treat vascular diseases
CN120209142A (zh) 一种靶向Ly6G6D的纳米抗体及其应用
EP1602726A2 (fr) Variants d'épissage associés à la tachykinine humaine et compositions les comprenant
CN111100211A (zh) 一种Fc融合蛋白及其应用
TW202200606A (zh) C4結合蛋白之C端片段與血管生成素-1之類纖維蛋白原結構域之間之嵌合融合作為治療血管疾病之血管生成素模擬物及Tie2促效劑
CN114621354A (zh) Fab-白蛋白结合肽融合蛋白及其制备方法和应用
US20040241639A1 (en) Human tachykinin-related splice variants and compositions thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24864734

Country of ref document: EP

Kind code of ref document: A1